ABSTRACT. This study evaluated the inhibitory effects of spironolactone, a non-selective aldosterone receptor antagonist, on hypertensioninduced myocardial fibrosis. Collagen I and III contents was detected in the myocardial tissue of spontaneously hypertensive rats (SHRs) after spironolactone administration. Twenty male SHRs were assigned to the spironolactone group or control group (N = 10 each); 7 Wistar-Kyoto rats (WKY) were also used. Spironolactone dissolved in ddH 2 O was administered via gavage at a dosage of 20 mg·kg -1 ·day -1 . Meanwhile, the control and WKY groups were administered equivalent volumes of ddH 2 O for 16 weeks. Western blotting was used to detect the contents of collagen I in myocardial tissue; observations were performed using polarizing microscopy, and the area integration and ratio of collagen I/ III were subsequently calculated. Compared to the WKY group, col-
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